Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV‐1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment‐naive as well as heavily pretreated HIV‐infected patients failin...
Gespeichert in:
| Veröffentlicht in: | Annals of the New York Academy of Sciences 2011-03, Vol.1222 (1), p.83-89 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 89 |
|---|---|
| container_issue | 1 |
| container_start_page | 83 |
| container_title | Annals of the New York Academy of Sciences |
| container_volume | 1222 |
| creator | Nguyen, Bach-Yen T. Isaacs, Robin D. Teppler, Hedy Leavitt, Randi Y. Sklar, Peter Iwamoto, Marian Wenning, Larissa A. Miller, Michael D. Chen, Joshua Kemp, Ramon Xu, Wei Fromtling, Robert A. Vacca, Joseph P. Young, Steven D. Rowley, Michael Lower, Michael W. Gottesdiener, Keith M. Hazuda, Daria J. |
| description | Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV‐1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment‐naive as well as heavily pretreated HIV‐infected patients failing therapy with multidrug‐resistant virus. Raltegravir has a favorable drug interaction profile that permits both administration to a wide, demographically diverse patient population and coadministration with many other therapeutic agents, including antiretroviral agents and supportive medications, without restrictions or dose adjustment. Data through 96 weeks of follow‐up in three phase III studies, protocol 021 (STARTMRK) in treatment‐naive patients, and protocols 018 (BENCHMRK‐1) and 019 (BENCHMRK‐2) in treatment‐experienced patients, demonstrated the potent and durable antiretroviral and immunologic effects and the favorable long‐term safety profile of raltegravir in both treatment‐naive and treatment‐experienced patients. Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection. |
| doi_str_mv | 10.1111/j.1749-6632.2011.05972.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_879472010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>879472010</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4482-2b343048518073855ee542d5f8385b19de70482e642091dac329cdfeb310fa3f3</originalsourceid><addsrcrecordid>eNqNkUtP3DAUha2qqAyPv1BF6qKrBD9ju4tKgMpDRVDRAqUby0luiqd5gJ3A8O_rzNBZdNN6YV_rfudYvgehhOCMxLU3z4jkOs1zRjOKCcmw0JJmi1dotm68RjOMpUyVpmwTbYUwx5hQxeUbtEkJZ1zzfIZuL20zwE9vH53_kAx3kNTOhyE5Ob1OSeK6ZS9AEgZvuyqZ9lCDj507V7ihn6qlLAoS61vbQjdY78Z2B23Utgmw-3Juo6ujT98OT9Kzi-PTw_2ztORc0ZQWjDPMlSAKS6aEABCcVqJW8VIQXYGMXQo5p1iTypaM6rKqoWAE15bVbBu9X_ne-_5hhDCY1oUSmsZ20I_BKKm5jEPC_yaFkormSkfy3V_kvB99F79hiMwljlPkIlJqRZW-D8FDbe69a61_NgSbKSczN1McZorDTDmZZU5mEaVvXx4YixaqtfBPMBH4uAKeXAPP_21szm_3v05lNEhXBi4MsFgbWP_L5JJJYW7Oj438zNnB9y8_zAH7DRafrmM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1767084745</pqid></control><display><type>article</type><title>Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Nguyen, Bach-Yen T. ; Isaacs, Robin D. ; Teppler, Hedy ; Leavitt, Randi Y. ; Sklar, Peter ; Iwamoto, Marian ; Wenning, Larissa A. ; Miller, Michael D. ; Chen, Joshua ; Kemp, Ramon ; Xu, Wei ; Fromtling, Robert A. ; Vacca, Joseph P. ; Young, Steven D. ; Rowley, Michael ; Lower, Michael W. ; Gottesdiener, Keith M. ; Hazuda, Daria J.</creator><creatorcontrib>Nguyen, Bach-Yen T. ; Isaacs, Robin D. ; Teppler, Hedy ; Leavitt, Randi Y. ; Sklar, Peter ; Iwamoto, Marian ; Wenning, Larissa A. ; Miller, Michael D. ; Chen, Joshua ; Kemp, Ramon ; Xu, Wei ; Fromtling, Robert A. ; Vacca, Joseph P. ; Young, Steven D. ; Rowley, Michael ; Lower, Michael W. ; Gottesdiener, Keith M. ; Hazuda, Daria J.</creatorcontrib><description>Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV‐1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment‐naive as well as heavily pretreated HIV‐infected patients failing therapy with multidrug‐resistant virus. Raltegravir has a favorable drug interaction profile that permits both administration to a wide, demographically diverse patient population and coadministration with many other therapeutic agents, including antiretroviral agents and supportive medications, without restrictions or dose adjustment. Data through 96 weeks of follow‐up in three phase III studies, protocol 021 (STARTMRK) in treatment‐naive patients, and protocols 018 (BENCHMRK‐1) and 019 (BENCHMRK‐2) in treatment‐experienced patients, demonstrated the potent and durable antiretroviral and immunologic effects and the favorable long‐term safety profile of raltegravir in both treatment‐naive and treatment‐experienced patients. Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection.</description><identifier>ISSN: 0077-8923</identifier><identifier>EISSN: 1749-6632</identifier><identifier>DOI: 10.1111/j.1749-6632.2011.05972.x</identifier><identifier>PMID: 21434946</identifier><identifier>CODEN: ANYAA9</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>AIDS ; Anti-HIV Agents - administration & dosage ; Anti-HIV Agents - chemical synthesis ; Anti-HIV Agents - therapeutic use ; Anti-Retroviral Agents - administration & dosage ; Anti-Retroviral Agents - therapeutic use ; Clinical Trials, Phase III as Topic ; HIV ; HIV Infections - drug therapy ; HIV Integrase - metabolism ; HIV Integrase Inhibitors - administration & dosage ; HIV Integrase Inhibitors - chemical synthesis ; HIV Integrase Inhibitors - therapeutic use ; HIV-1 ; HIV-1 - drug effects ; HIV-1 - physiology ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Humans ; integrase inhibitor ; Protease inhibitors ; Pyrrolidinones - administration & dosage ; Pyrrolidinones - adverse effects ; Pyrrolidinones - chemical synthesis ; Pyrrolidinones - therapeutic use ; raltegravir ; Raltegravir Potassium ; Treatment Outcome</subject><ispartof>Annals of the New York Academy of Sciences, 2011-03, Vol.1222 (1), p.83-89</ispartof><rights>2011 New York Academy of Sciences</rights><rights>2011 New York Academy of Sciences.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4482-2b343048518073855ee542d5f8385b19de70482e642091dac329cdfeb310fa3f3</citedby><cites>FETCH-LOGICAL-c4482-2b343048518073855ee542d5f8385b19de70482e642091dac329cdfeb310fa3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1749-6632.2011.05972.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1749-6632.2011.05972.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21434946$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nguyen, Bach-Yen T.</creatorcontrib><creatorcontrib>Isaacs, Robin D.</creatorcontrib><creatorcontrib>Teppler, Hedy</creatorcontrib><creatorcontrib>Leavitt, Randi Y.</creatorcontrib><creatorcontrib>Sklar, Peter</creatorcontrib><creatorcontrib>Iwamoto, Marian</creatorcontrib><creatorcontrib>Wenning, Larissa A.</creatorcontrib><creatorcontrib>Miller, Michael D.</creatorcontrib><creatorcontrib>Chen, Joshua</creatorcontrib><creatorcontrib>Kemp, Ramon</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Fromtling, Robert A.</creatorcontrib><creatorcontrib>Vacca, Joseph P.</creatorcontrib><creatorcontrib>Young, Steven D.</creatorcontrib><creatorcontrib>Rowley, Michael</creatorcontrib><creatorcontrib>Lower, Michael W.</creatorcontrib><creatorcontrib>Gottesdiener, Keith M.</creatorcontrib><creatorcontrib>Hazuda, Daria J.</creatorcontrib><title>Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium</title><title>Annals of the New York Academy of Sciences</title><addtitle>Ann N Y Acad Sci</addtitle><description>Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV‐1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment‐naive as well as heavily pretreated HIV‐infected patients failing therapy with multidrug‐resistant virus. Raltegravir has a favorable drug interaction profile that permits both administration to a wide, demographically diverse patient population and coadministration with many other therapeutic agents, including antiretroviral agents and supportive medications, without restrictions or dose adjustment. Data through 96 weeks of follow‐up in three phase III studies, protocol 021 (STARTMRK) in treatment‐naive patients, and protocols 018 (BENCHMRK‐1) and 019 (BENCHMRK‐2) in treatment‐experienced patients, demonstrated the potent and durable antiretroviral and immunologic effects and the favorable long‐term safety profile of raltegravir in both treatment‐naive and treatment‐experienced patients. Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection.</description><subject>AIDS</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Anti-HIV Agents - chemical synthesis</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Anti-Retroviral Agents - administration & dosage</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Integrase - metabolism</subject><subject>HIV Integrase Inhibitors - administration & dosage</subject><subject>HIV Integrase Inhibitors - chemical synthesis</subject><subject>HIV Integrase Inhibitors - therapeutic use</subject><subject>HIV-1</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - physiology</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>integrase inhibitor</subject><subject>Protease inhibitors</subject><subject>Pyrrolidinones - administration & dosage</subject><subject>Pyrrolidinones - adverse effects</subject><subject>Pyrrolidinones - chemical synthesis</subject><subject>Pyrrolidinones - therapeutic use</subject><subject>raltegravir</subject><subject>Raltegravir Potassium</subject><subject>Treatment Outcome</subject><issn>0077-8923</issn><issn>1749-6632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtP3DAUha2qqAyPv1BF6qKrBD9ju4tKgMpDRVDRAqUby0luiqd5gJ3A8O_rzNBZdNN6YV_rfudYvgehhOCMxLU3z4jkOs1zRjOKCcmw0JJmi1dotm68RjOMpUyVpmwTbYUwx5hQxeUbtEkJZ1zzfIZuL20zwE9vH53_kAx3kNTOhyE5Ob1OSeK6ZS9AEgZvuyqZ9lCDj507V7ihn6qlLAoS61vbQjdY78Z2B23Utgmw-3Juo6ujT98OT9Kzi-PTw_2ztORc0ZQWjDPMlSAKS6aEABCcVqJW8VIQXYGMXQo5p1iTypaM6rKqoWAE15bVbBu9X_ne-_5hhDCY1oUSmsZ20I_BKKm5jEPC_yaFkormSkfy3V_kvB99F79hiMwljlPkIlJqRZW-D8FDbe69a61_NgSbKSczN1McZorDTDmZZU5mEaVvXx4YixaqtfBPMBH4uAKeXAPP_21szm_3v05lNEhXBi4MsFgbWP_L5JJJYW7Oj438zNnB9y8_zAH7DRafrmM</recordid><startdate>201103</startdate><enddate>201103</enddate><creator>Nguyen, Bach-Yen T.</creator><creator>Isaacs, Robin D.</creator><creator>Teppler, Hedy</creator><creator>Leavitt, Randi Y.</creator><creator>Sklar, Peter</creator><creator>Iwamoto, Marian</creator><creator>Wenning, Larissa A.</creator><creator>Miller, Michael D.</creator><creator>Chen, Joshua</creator><creator>Kemp, Ramon</creator><creator>Xu, Wei</creator><creator>Fromtling, Robert A.</creator><creator>Vacca, Joseph P.</creator><creator>Young, Steven D.</creator><creator>Rowley, Michael</creator><creator>Lower, Michael W.</creator><creator>Gottesdiener, Keith M.</creator><creator>Hazuda, Daria J.</creator><general>Blackwell Publishing Inc</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7ST</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>SOI</scope><scope>7X8</scope><scope>7T2</scope><scope>7U2</scope></search><sort><creationdate>201103</creationdate><title>Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium</title><author>Nguyen, Bach-Yen T. ; Isaacs, Robin D. ; Teppler, Hedy ; Leavitt, Randi Y. ; Sklar, Peter ; Iwamoto, Marian ; Wenning, Larissa A. ; Miller, Michael D. ; Chen, Joshua ; Kemp, Ramon ; Xu, Wei ; Fromtling, Robert A. ; Vacca, Joseph P. ; Young, Steven D. ; Rowley, Michael ; Lower, Michael W. ; Gottesdiener, Keith M. ; Hazuda, Daria J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4482-2b343048518073855ee542d5f8385b19de70482e642091dac329cdfeb310fa3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>AIDS</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Anti-HIV Agents - chemical synthesis</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Anti-Retroviral Agents - administration & dosage</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Integrase - metabolism</topic><topic>HIV Integrase Inhibitors - administration & dosage</topic><topic>HIV Integrase Inhibitors - chemical synthesis</topic><topic>HIV Integrase Inhibitors - therapeutic use</topic><topic>HIV-1</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - physiology</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>integrase inhibitor</topic><topic>Protease inhibitors</topic><topic>Pyrrolidinones - administration & dosage</topic><topic>Pyrrolidinones - adverse effects</topic><topic>Pyrrolidinones - chemical synthesis</topic><topic>Pyrrolidinones - therapeutic use</topic><topic>raltegravir</topic><topic>Raltegravir Potassium</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, Bach-Yen T.</creatorcontrib><creatorcontrib>Isaacs, Robin D.</creatorcontrib><creatorcontrib>Teppler, Hedy</creatorcontrib><creatorcontrib>Leavitt, Randi Y.</creatorcontrib><creatorcontrib>Sklar, Peter</creatorcontrib><creatorcontrib>Iwamoto, Marian</creatorcontrib><creatorcontrib>Wenning, Larissa A.</creatorcontrib><creatorcontrib>Miller, Michael D.</creatorcontrib><creatorcontrib>Chen, Joshua</creatorcontrib><creatorcontrib>Kemp, Ramon</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Fromtling, Robert A.</creatorcontrib><creatorcontrib>Vacca, Joseph P.</creatorcontrib><creatorcontrib>Young, Steven D.</creatorcontrib><creatorcontrib>Rowley, Michael</creatorcontrib><creatorcontrib>Lower, Michael W.</creatorcontrib><creatorcontrib>Gottesdiener, Keith M.</creatorcontrib><creatorcontrib>Hazuda, Daria J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Environment Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, Bach-Yen T.</au><au>Isaacs, Robin D.</au><au>Teppler, Hedy</au><au>Leavitt, Randi Y.</au><au>Sklar, Peter</au><au>Iwamoto, Marian</au><au>Wenning, Larissa A.</au><au>Miller, Michael D.</au><au>Chen, Joshua</au><au>Kemp, Ramon</au><au>Xu, Wei</au><au>Fromtling, Robert A.</au><au>Vacca, Joseph P.</au><au>Young, Steven D.</au><au>Rowley, Michael</au><au>Lower, Michael W.</au><au>Gottesdiener, Keith M.</au><au>Hazuda, Daria J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><addtitle>Ann N Y Acad Sci</addtitle><date>2011-03</date><risdate>2011</risdate><volume>1222</volume><issue>1</issue><spage>83</spage><epage>89</epage><pages>83-89</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><coden>ANYAA9</coden><abstract>Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV‐1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment‐naive as well as heavily pretreated HIV‐infected patients failing therapy with multidrug‐resistant virus. Raltegravir has a favorable drug interaction profile that permits both administration to a wide, demographically diverse patient population and coadministration with many other therapeutic agents, including antiretroviral agents and supportive medications, without restrictions or dose adjustment. Data through 96 weeks of follow‐up in three phase III studies, protocol 021 (STARTMRK) in treatment‐naive patients, and protocols 018 (BENCHMRK‐1) and 019 (BENCHMRK‐2) in treatment‐experienced patients, demonstrated the potent and durable antiretroviral and immunologic effects and the favorable long‐term safety profile of raltegravir in both treatment‐naive and treatment‐experienced patients. Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>21434946</pmid><doi>10.1111/j.1749-6632.2011.05972.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0077-8923 |
| ispartof | Annals of the New York Academy of Sciences, 2011-03, Vol.1222 (1), p.83-89 |
| issn | 0077-8923 1749-6632 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_879472010 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | AIDS Anti-HIV Agents - administration & dosage Anti-HIV Agents - chemical synthesis Anti-HIV Agents - therapeutic use Anti-Retroviral Agents - administration & dosage Anti-Retroviral Agents - therapeutic use Clinical Trials, Phase III as Topic HIV HIV Infections - drug therapy HIV Integrase - metabolism HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - chemical synthesis HIV Integrase Inhibitors - therapeutic use HIV-1 HIV-1 - drug effects HIV-1 - physiology Human immunodeficiency virus Human immunodeficiency virus 1 Humans integrase inhibitor Protease inhibitors Pyrrolidinones - administration & dosage Pyrrolidinones - adverse effects Pyrrolidinones - chemical synthesis Pyrrolidinones - therapeutic use raltegravir Raltegravir Potassium Treatment Outcome |
| title | Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A14%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Raltegravir:%20the%20first%20HIV-1%20integrase%20strand%20transfer%20inhibitor%20in%20the%20HIV%20armamentarium&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=Nguyen,%20Bach-Yen%20T.&rft.date=2011-03&rft.volume=1222&rft.issue=1&rft.spage=83&rft.epage=89&rft.pages=83-89&rft.issn=0077-8923&rft.eissn=1749-6632&rft.coden=ANYAA9&rft_id=info:doi/10.1111/j.1749-6632.2011.05972.x&rft_dat=%3Cproquest_cross%3E879472010%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1767084745&rft_id=info:pmid/21434946&rfr_iscdi=true |